1. Real-world long-term effectiveness of ustekinumab in Crohn’s disease: results from the ENEIDA registry.
Iborra M., Beltrán B., Fernández-Clotet A., et al. [published online ahead of print, 2020 Aug 8]. Aliment Pharmacol Ther. 2020;10.1111/apt.15958. doi:10.1111/apt.15958

2. Panenteric capsule endoscopy identifies proximal small bowel disease guiding upstaging and treatment intensification in Crohn’s disease: A European multicentre observational cohort study.
Tai FWD, Ellul P., Elosua A., et al. [published online ahead of print, 2020 Aug 2]. United European Gastroenterol J. 2020;2050640620948664. doi:10.1177/2050640620948664

3. Recurrent granulomatous cheilitis associated with Crohn’s disease successfully treated with ustekinumab: case report and literature review.
Taxonera C., Alba C., Colmenares M., Olivares D., Rey E. Therap Adv Gastroenterol. 2020;13:1756284820934327. Published 2020 Jul 27. doi:10.1177/1756284820934327

4. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn’s disease.
Rodríguez-Lago I., Hoyo J.D., Pérez-Girbés A., et al. [published online ahead of print, 2020 Jul 28]. United European Gastroenterol J. 2020;2050640620947579. doi:10.1177/2050640620947579

5. The use of 5-aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow-up – an Epi-IBD study.
Burisch J., Bergemalm D., Halfvarson J., et al. [published online ahead of print, 2020 Jul 26]. United European Gastroenterol J. 2020;2050640620945949. doi:10.1177/2050640620945949

6. Ustekinumab in Crohn’s disease: effectiveness and safety in clinical practice.
Saldaña Dueñas C., Rullán Iriarte M., Elosua González A., Rodríguez Gutiérrez C., Rubio Iturria S., Nantes Castillejo Ó. [published online ahead of print, 2020 Jul 20]. Gastroenterol Hepatol. 2020;S0210-5705(20)30157-6. doi:10.1016/j.gastrohep.2020.01.014

7. Surgery for Crohn’s disease during pregnancy: a difficult decision.
Chaparro M., Gisbert J.P. United European Gastroenterol J. 2020;8(6):633-634. doi:10.1177/2050640620928181

8. Duodenal Crohn’s disease – gastro-jejunal bypass versus duodenal-jejunal bypass – a video vignette.
Elorza-Echaniz G., Aguirre-Allende I., Borda-Arrizabalaga N., Eizaguirre-Letamendia E., Enriquez-Navascues J.M. [published online ahead of print, 2020 Jun 18]. Colorectal Dis. 2020;10.1111/codi.15202. doi:10.1111/codi.15202

9. Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease.
Sánchez-Hernández J.G., Pérez-Blanco J.S., Rebollo N., Muñoz F., Prieto V., Calvo M.V. Eur J Pharm Sci. 2020;150:105369. doi:10.1016/j.ejps.2020.105369

10. Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
Kopylov U., Hanzel J., Liefferinckx C., et al. Aliment Pharmacol Ther. 2020;52(1):135-142. doi:10.1111/apt.15784

11. Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study.
Marin-Jimenez I., Bastida G., Forés A., et al. BMJ Open Gastroenterol. 2020;7(1):e000351. Published 2020 Mar 26. doi:10.1136/bmjgast-2019-000351

12. The prevention and management of Crohn’s disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey.
Dragoni G., Ding N., Gecse K.B., et al. [published online ahead of print, 2020 Apr 10]. Eur J Gastroenterol Hepatol. 2020;10.1097/MEG.0000000000001729. doi:10.1097/MEG.0000000000001729

13. The effect of a mindfulness-based therapy on different biomarkers among patients with inflammatory bowel disease: a randomised controlled trial.
González-Moret R., Cebolla A., Cortés X., et al. Sci Rep. 2020;10(1):6071. Published 2020 Apr 8. doi:10.1038/s41598-020-63168-4

14. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn’s disease.
Chaparro M., Guerra I., Iborra M., et al. Eur J Gastroenterol Hepatol. 2020;32(5):588-596. doi:10.1097/MEG.0000000000001706

15. Video-laparoscopic assessment of the small bowel in Crohn’s disease: a comparative study to evaluate surgeons’ inter-observer variability.
Celentano V., Garofalo E., Spinelli A., et al. [published online ahead of print, 2020 Apr 2]. Surg Endosc. 2020;10.1007/s00464-020-07521-8. doi:10.1007/s00464-020-07521-8

16. Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease.
Ungaro R.C., Yzet C., Bossuyt P., et al. Gastroenterology. 2020;159(1):139-147. doi:10.1053/j.gastro.2020.03.039

17. Management and outcomes of patients with Crohn’s disease with first vs multiple surgeries: results from the PRACTICROHN study.
Iborra M., Juliá B., Martín Arranz M.D., et al. Gastroenterol Rep (Oxf). 2019;7(6):411-418. Published 2019 Jul 19. doi:10.1093/gastro/goz029

18. Adaptation of TECCU App Based on Patients´ Perceptions for the Telemonitoring of Inflammatory Bowel Disease: A Qualitative Study Using Focus Groups.
Del Hoyo J.D., Nos P., Faubel R., et al. Int J Environ Res Public Health. 2020;17(6):1871. Published 2020 Mar 13. doi:10.3390/ijerph17061871

19. Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease.
Rodríguez-Lago I., Castro-Poceiro J., Fernández-Clotet A., et al. Aliment Pharmacol Ther. 2020;51(9):870-879. doi:10.1111/apt.15687

20. Effects of anti-TNF-alpha therapy on hemoglobin levels and anemia in patients with inflammatory bowel disease.
Lucendo A.J., Roncero Ó., Serrano-Duenas M.T., et al. Dig Liver Dis. 2020;52(4):400-407. doi:10.1016/j.dld.2019.11.019

21. Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?
Torres P., Cañete F., Núñez L., et al. Dig Dis Sci. 2020;65(7):2036-2043. doi:10.1007/s10620-019-06010-w

22. Autologous Platelet-Rich Plasma in the Treatment of Perianal Fistula in Crohn’s Disease.
de la Portilla F., Jiménez-Salido A., Araujo-Miguez A., et al. [published online ahead of print, 2019 Dec 10]. J Gastrointest Surg. 2019;10.1007/s11605-019-04480-x. doi:10.1007/s11605-019-04480-x

23. Telemonitoring of Crohn’s Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis.
Del Hoyo J., Nos P., Bastida G., et al.  J Med Internet Res. 2019;21(9):e15505. Published 2019 Sep 13. doi:10.2196/15505

24. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.
Casanova M.J., Chaparro M., Mínguez M., et al. Inflamm Bowel Dis. 2020;26(4):606-616. doi:10.1093/ibd/izz192

25. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data.
Guerra Veloz M.F., Belvis Jiménez M., Valdes Delgado T., et al. Therap Adv Gastroenterol. 2019;12:1756284819858052. Published 2019 Jun 18. doi:10.1177/1756284819858052

26. Restorative surgery for ulcerative colitis in the elderly: an analysis of ileal pouch-anal anastomosis procedures from the American College of Surgeons National Surgical Quality Improvement Program.
Pellino G., Reif de Paula T., Lawlor G., Keller D.S. [published online ahead of print, 2020 Aug 16]. Tech Coloproctol. 2020;10.1007/s10151-020-02327-1. doi:10.1007/s10151-020-02327-1

27. Evolution of endoscopic lesions in steroid-refractory acute severe ulcerative colitis responding to infliximab or cyclosporine.
Laharie D., Bourreille A., Branche J., et al. [published online ahead of print, 2020 Aug 7]. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)31078-8. doi:10.1016/j.cgh.2020.08.001

28. Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis ? An international multicentric retrospective study in 72 patients.
Frontali A., Cohen L., Bridoux V., et al. [published online ahead of print, 2020 Jun 4]. J Crohns Colitis. 2020;jjaa107. doi:10.1093/ecco-jcc/jjaa107

29. Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study.
Marti-Aguado D., Ballester M.P., Tosca J., et al. United European Gastroenterol J. 2019;7(8):1042-1050. doi:10.1177/2050640619854277